2019
DOI: 10.1016/j.chom.2018.12.005
|View full text |Cite
|
Sign up to set email alerts
|

A Two-Antibody Pan-Ebolavirus Cocktail Confers Broad Therapeutic Protection in Ferrets and Nonhuman Primates

Abstract: SUMMARY Recent and ongoing outbreaks of Ebola virus disease (EVD) underscore the unpredictable nature of ebolavirus reemergence and the urgent need for antiviral treatments. Unfortunately, available experimental vaccines and immunotherapeutics are specific for a single member of the Ebolavirus genus, Ebola virus (EBOV), and ineffective against other ebolaviruses associated with EVD, including Sudan virus (SUDV) and Bundibugyo virus (BDBV). Here we show that MBP134AF, a pan-ebolavirus therapeutic comprising two… Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

0
89
1

Year Published

2019
2019
2024
2024

Publication Types

Select...
5
1
1

Relationship

1
6

Authors

Journals

citations
Cited by 96 publications
(90 citation statements)
references
References 24 publications
0
89
1
Order By: Relevance
“…Outbreaks of filovirus disease have become increasingly difficult to manage due to increased connectivity in endemic regions coupled with inadequate public health infrastructures and lack of approved medical countermeasures including diagnostics, therapeutics, and vaccines. Due to the sporadic nature of these outbreaks, the development and efficacy testing of preventative vaccines and postexposure treatments has previously been limited to animal models, including nonhuman primates, in which complete protection from lethal EBOV challenge has been demonstrated 7-9 . The unprecedented magnitude of the 2013-16 West African EBOV epidemic offered a unique opportunity to assess the efficacy of some of the most promising medical countermeasures available at that time 7,8 .…”
Section: Figurementioning
confidence: 99%
See 2 more Smart Citations
“…Outbreaks of filovirus disease have become increasingly difficult to manage due to increased connectivity in endemic regions coupled with inadequate public health infrastructures and lack of approved medical countermeasures including diagnostics, therapeutics, and vaccines. Due to the sporadic nature of these outbreaks, the development and efficacy testing of preventative vaccines and postexposure treatments has previously been limited to animal models, including nonhuman primates, in which complete protection from lethal EBOV challenge has been demonstrated 7-9 . The unprecedented magnitude of the 2013-16 West African EBOV epidemic offered a unique opportunity to assess the efficacy of some of the most promising medical countermeasures available at that time 7,8 .…”
Section: Figurementioning
confidence: 99%
“…In order to address the potential issue of vaccine/therapeutic or therapeutic/vaccine interference we employed a uniformly lethal rhesus macaque model of EBOV infection 9 . In brief, sixteen animals were divided into three experimental groups (n=5/group) and one control animal.…”
Section: Figurementioning
confidence: 99%
See 1 more Smart Citation
“…Pan-Ebolavirus immunotherapy would provide a rapid-response treatment during Ebola virus outbreaks. In this issue of Cell Host & Microbe, Wec et al (2019) and Bornholdt et al (2019) optimize the MBP134 mAb cocktail through antibody affinity maturation, improving its protective efficacy against three Ebolaviruses: EBOV, SUDV, and BDBV.…”
mentioning
confidence: 99%
“…This candidate was combined with a second mAb to develop the MBP-134 cocktail with optimized effector functions, demonstrating protection mice and guinea pigs against all three viruses. The companion paper by Bornholdt et al (2019) demonstrates that the MBP-134 cocktail is highly protective in ferrets and non-human primates against EBOV, BDBV, and SUDV.…”
mentioning
confidence: 99%